Feasibility of ECG-Based Glucose Monitoring System
Feasibility Assessment of Novel ECG-Based Continuous Glucose Monitoring System
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jasper Yang, Ph.D.
- Phone Number: 886 3667 5801
- Email: jasper@singularwings.com
Study Contact Backup
- Name: Jesse Liao
- Phone Number: 886 3667 5801
- Email: jesse@singularwings.com
Study Locations
-
-
-
Taoyuan, Taiwan
- Recruiting
- Landseed International Hospital
-
Contact:
- Yi-Shu Chang
- Phone Number: 886-3494-1234
- Email: changys@landseed.com.tw
-
Contact:
- Ying-Kuang Lin, M.D. Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Males and females, age 18 years or older.
- Subjects can communicate clearly, fully understand the informed consent form, and are aware of the rights and obligations of the study.
- Category 1: Subjects without a medical history of hyperglycemia / hypoglycemia or type 1 / type 2 diabetes.
Category 2: Subjects having diabetes mellitus (DM) and HbA1c value of. 5.5% to 10%, with eGFR ≥ 60 mL/min.
Category 3: Subjects having chronic kidney disease (CKD) and diabetes. mellitus (DM), with eGFR < 60 mL/min.
• Willing and able to participate in all aspects of the study.
Exclusion Criteria:
- Subjects suffering from insomnia or severe digestive system disorders within 3 months prior to the screening visit.
- Subjects who are addicted to alcohol or caffeine.
- Existing severe cardiac conditions such as recent myocardial infarction or advanced heart failure within 6 months prior to the screening visit.
- Has experienced an episode of confirmed or suspected diabetic ketoacidosis (DKA) within 6 months prior to the screening visit.
- Subjects who are vulnerable groups or with higher risks, such as HIV carriers, pregnant women or planning to become pregnant within the study duration, breast-feeding mothers, subjects with rare diseases, physical disabilities, incurable fatal diseases, dependents in nursing homes, incapacity, or intellectual or mental disabilities.
- Has a concomitant disease or condition that may compromise subject safety such as unstable coronary heart disease, cystic fibrosis, serious psychiatric disorder, or any other uncontrolled medical conditions.
- Any active infection or malignancy requiring acute therapy.
- Having coagulation disorders.
- Has known allergy to medical adhesives.
- Subjects using any cardiac related implantable medical devices such as a pacemaker and so on.
- Subjects on certain drugs known to cause arrhythmias or significantly impact kidney function or blood glucose levels (except for the current daily use medication).
- Subjects have used defibrillators within 3 months prior to the screening visit.
- Currently participating in another device or drug study.
- Currently receiving dialysis treatment or planning to receive dialysis during the study.
- Any other clinical condition that, in the investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Monitoring arm
Subjects will wear a portable ECG recorder to monitor ECG information and use 3 blood glucose monitoring methods to monitor blood glucose level over time.
|
No intervention is conducted in this study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To assess the accuracy of glucose level determined by the glucose detection model through ECG data and blood glucose monitoring values.
Time Frame: 14 days
|
Part of the ECG and glucose data will be used for AI model training, and the rest will be used for accuracy testing (such as through the comparison of mean absolute relative difference (MARD) between glucose levels from different methods).
|
14 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ying-Kuang Lin, M.D. Ph.D., Landseed International Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SWM-BG-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.